FOXM1 and central nervous system cancer: Univariate Cox regression analysis indicated that the clinical stage (HR = 1.833, 95% CI: 1.395–2.409, p < 0.001) and high expression of MYBL2 (HR = 3.619, 95% CI: 2.075–6.313, p < 0.001) and FoxM1 (HR = 0.336, 95% CI: 0.187–0.602, p < 0.001) were unfavorable prognostic factor in glioma patients (Tables 4 and 5).